samedi 10 octobre 2026
RechercherExplore
fr.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· July 20, 2026

Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer

View original at globenewswire.com
Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer First patient dosed in Phase 3 LUTEON1 trial evaluating TLX250-Tx in relapsed or recurrent clear cell renal cell carcinoma (ccRCC).LUTEON is the first Phase 3 study of a CAIX2-targeted radiopharmaceutical therapy in ccRCC…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Dosing the first patient in LUTEON marks an important milestone; despite advances in care, outcomes remain poor for many ccRCC patients, underscoring the need for innovative therapeutic approaches, and the study will evaluate the safety, tolerability and efficacy of TLX250-Tx.

    60% confidence

  • LUTEON represents the next stage in Telix's global clinical development of TLX250-Tx, which is designed to use the high prevalence of CAIX expression in ccRCC to deliver targeted radiation to tumor sites while limiting exposure to healthy tissue.

    60% confidence

Cité dans ces articles de Via News

Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Agentic Enterprise Software Consolidates: Big Platforms Push Autonomy While Startups Get Absorbed
Enterprise software is shifting toward autonomous, AI-agent-driven products. SAP (Autonomous Enterprise, Joule), Meta (a new Enterprise Platform led by ex-MongoDB CEO Chirantan Desai) and UiPath (raised guidance) are pushing from the top. Meanwhile AI-security and governance startups are being acquired (Fortinet–Virtue AI, Harvey–Guardrails AI, Tiny–Oso Cloud) and seed-stage agent companies keep raising capital (Dextr, Latitude, Groq). Investors such as Norwest's Sean Jacobsohn see finance and ERP back-office software as the easier area to disrupt. Trust and enforced governance are treated as preconditions for regulated sectors like finance, and AI is judged unreliable for calculations.
Notre lecture des données ›
Signaux que nous suivons
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Tendances que nous surveillons ›
Là où les sources divergent
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,986
faits reliés à leur source — et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,986 faits vérifiés avec la source5,365 documents sources archivés
Interrogez ces données → isubstrate.com